Solving the Problem of Verifying Vaccinations

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

The pandemic has strained healthcare systems beyond compare, but there’s renewed hope for all with the vaccine now available. However, the rollout for vaccines has been challenging, and the next biggest hurdle is how to verify vaccine documentation. Host Kevin Stevenson spoke with Mike Joyce, Client Strategist and Engagement Partner, at Theorem. Theorem is an innovation and engineering firm that solves complex challenges for the world’s most admired organizations. The organization built a mHealth Platform for AT&T to share clinical data in a compliant and secure manner.

Verifying vaccinations is both a complex and simple problem. “Transmitting verifiable information through secure tunnels and layers of trust isn’t new. Implementing is the real problem,” Joyce said.

The challenge stems from multiple stakeholders and a fragmented healthcare system.

“With a digital certificate, the issue is we don’t know where it’s going to be used. Investment in a system designed to accommodate flexibility will be key,” Joyce added.

In breaking down the parties involved, there are the holders (consumers), the central authority (issuer), and the verifying party. The move to require vaccines for certain activities is likely coming. The verifiable platform will also need to be global.

The technology is already there. Microsoft, Salesforce, and Oracle are developing a digital solution to access COVID-19 vaccination records, but that’s just the first part. “Technology is great in developing the scaffold. Regulators need to take the next step for consistency in the process,” Joyce shared.

Privacy and security are another issue, but Joyce noted that the cryptographic protocols already exist for protecting sensitive data. The looming constraint is infrastructure. “someone has to write the software to integrate with healthcare records and appointment platforms. It will require more investment than a paper-based method. There’s a systemic issue in healthcare with sharing data,” he said.

Listen to Previous Episodes of MarketScale’s I Don’t Care Right Here!

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More